01—Abstract
Summary
Summary of the 10-K filed February 25, 2011. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation's 2010 Form 10-K reports net sales of $1.51 billiona, up 14% from $1.33 billion in 2009, with organic sales up 12% and acquisitions contributing 3%.
Operating income rose 35% to $249.1 millionb, operating margin expanded to 16.5% from 13.9%, and net income increased 39% to $157.1 million. Diluted EPS was $1.90, compared with $1.40 in 2009. Gross margin improved 160 basis points to 40.9%, driven by higher volume, restructuring-related cost reductions and product mix.
The company operates four reportable segments: Fluid & Metering Technologies (48% of 2010 sales, 44% of operating income), Health & Science Technologies (26% and 28%), Dispensing Equipment (8% and 7%), and Fire & Safety/Diversified Products (18% and 21%). Operating cash flow was $184.5 millionc, with capital expenditures of $32.8 million. Cash and cash equivalents rose to $235.1 million at year end, while total borrowings increased to $527.9 million after the issuance of $300.0 million of 4.5% Senior Notes due 2020 and €81.0 million of 2.58% Senior Euro Notes due 2015.
The company was in compliance with its financial covenants at December 31, 2010. For 2011, the filing states that IDEX expects mid-to-high single-digit organic growth, approximately 4% acquisition-related growth, and fully diluted EPS of $2.23 to $2.33d.
Subsequent events include the January 2011 acquisition of Advanced Thin Films (approximately $32.0 million cash) and a merger agreement to acquire Microfluidics International at $1.35 per share in cash. The Credit Facility and Term Loan both mature on December 21, 2011, and management intends to enter a new revolving credit facility during 2011.
02—Key points
Key Highlights
- Net sales rose 14% to $1,513.1 million; organic sales grew 12% and acquisitions added 3%.
- Operating margin reached 16.5%, up from 13.9% in 2009; operating income increased 35% to $249.1 million.
- Net income grew 39% to $157.1 million; diluted EPS was $1.90 versus $1.40 in 2009.
- Health & Science Technologies posted the strongest segment growth, with sales up 31% to $397.2 million and an operating margin of 20.7%.
- Balance sheet strengthened: cash rose to $235.1 million, and the company issued $300.0 million of 4.5% Senior Notes due 2020 to repay $250.0 million of Credit Facility borrowings.
- 2011 guidance calls for mid-to-high single-digit organic growth and fully diluted EPS of $2.23 to $2.33.
- Pending growth moves include the January 2011 Advanced Thin Films acquisition and a merger agreement for Microfluidics International at $1.35 per share in cash.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2010, Idex kept $0.10.
- Revenue$1.51B100.0%
- Cost of revenue−$894.6M59.1%
- Gross profit$618.5M40.9%
- Operating costs−$369.4M24.4%
- Operating income$249.1M16.5%
- Interest, other & tax−$92.0M6.1%
- Net income$157.1M10.4%
Where FY2010 revenue went
$1.51B- Cost of revenue: $894.6M, 59% of revenue
- SG&A: $358.3M, 24% of revenue
- Net income: $157.1M, 10% of revenue
- R&D: $31.8M, 2.1% of revenue
- Interest, other & tax: $92.0M, 6.1% of revenue
Kept 10% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 25, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $1.51B$1.33B | +13.8% |
| Cost of Revenue | $894.59M$807.27M | +10.8% |
| Gross Profit | $618.48M$522.39M | +18.4% |
| R&D Expenses | $31.80M$29.60M | +7.4% |
| SG&A Expenses | $358.27M$325.45M | +10.1% |
| Operating Income | $249.12M$184.85M | +34.8% |
| Interest Expense | $16.15M$17.18M | −6.0% |
| Net Income | $157.10M$113.39M | +38.5% |
| EPS (Basic) | $1.93$1.41 | +36.9% |
| EPS (Diluted) | $1.90$1.40 | +35.7% |
| Shares Outstanding (Basic) | 80.47M79.72M | +0.9% |
| Shares Outstanding (Diluted) | 81.98M80.73M | +1.6% |
05—Questions
Frequently Asked Questions
What drove the improvement in 2010 profitability?
The filing attributes the increase in gross margin and operating income primarily to higher sales volume, cost reductions from restructuring initiatives, and changes in product mix. Restructuring expenses were $11.1 million in 2010 compared with $12.1 million in 2009, and SG&A rose to $358.3 million from $325.5 million, largely due to volume-related expenses and acquisition costs.
How is IDEX financing its debt and what are its near-term maturities?
Total borrowings were $527.9 million at December 31, 2010, including $119.4 million classified as current. The current portion consists mainly of $27.8 million outstanding under the $600.0 million Credit Facility and $90.0 million under the Term Loan, both maturing December 21, 2011. Management intends to enter a new revolving credit facility in 2011 and expects cash and operating cash flow to be adequate to repay these balances.
What are the main risks highlighted in the filing?
Key risks include economic and industry slowdowns in its largest end markets, international operations (49% of 2010 sales were outside the U.S.), foreign currency exchange rate movements, competition, raw material availability, dependence on acquisitions and their integration, and goodwill and intangible assets totaling $1,207.0 million and $281.4 million, respectively, which could be impaired.
What is the company's outlook for 2011?
The company expects organic growth in the mid-to-high single digits and acquisition-related growth of approximately 4% from transactions completed in 2010, plus two acquisitions expected to close in the first quarter of 2011. It forecasts fully diluted EPS of $2.23 to $2.33 for the full year 2011.
06—Continue